A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)
The purpose of this study is to compare the efficacy of pomalidomide and low dose
dexamethasone with pembrolizumab (MK-3475) to that of pomalidomide and low dose
dexamethasone without pembrolizumab in terms of Progression-Free Survival (PFS) in
participants with refractory or relapsed and refractory multiple myeloma (rrMM) who have
undergone at least 2 lines of prior treatment.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society